In a target trial emulation using N3C data, adults prescribed metformin within six days of SARS-CoV-2 infection had about half the risk of long COVID or death within six months.
|Videos|June 8, 2020
Contagion Live News Network: WHO Official Remarks on Asymptomatic Spread of SARS-CoV-2
Author(s)Contagion® Editorial Staff
A quick brief on today's top infectious disease news.
Advertisement
Segment Description: A brief update on today's top infectious disease news.
Related Coverage: California COVID-19 Epidemic Driven by Multiple Viral Strains
As more information about SARS-CoV-2 emerges, mediators of pandemic outcomes not associated with public health measures can be better controlled for. Viral strain is a key biological variable, among others, in understanding why regions with similar policies have not always had parallel outcomes during the coronavirus disease 2019 (COVID-19) crisis.
Analysis of SARS-CoV-2 genomes from a small cohort of patients in California, published by investigators in Science, show that the virus arrived in Northern California through a complicated series of introductions internationally and between states.
Genomic surveillance was conducted through a new method called Metagenomic Sequencing with Spiked Primer Enrichment (MSSPE).
Read the
Advertisement
Related to this article
Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute infection and more than a quarter had completely remitted, in a large prospective cohort study.
Deborah Fuller, PhD, provides commentary around the data, and advantages of the technology.
Confirmed US measles cases rose 6.8% this week to 5,182, more than double the 2025 total, as three states reported measles-associated deaths.
A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Advertisement
Advertisement